Key facts
- This page summarizes Bethany Sensenig's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2025, 17:41.
Bethany Sensenig - 22 Feb 2025 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Reporting relationship
- Director
- Issuer ticker
- SUPN
- Reported as of
- 22 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2025, 17:41:09 UTC
- Prior SEC filing
- 21 Feb 2025
- Next SEC filing
- 18 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Bethany Sensenig filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 24 Feb 2025.
Change
- Previous filing in this sequence was filed on 21 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SUPN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +5,369
- Change %
- Price
- $0.000000
- Shares after
- 5,369
- Date
- 22 Feb 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SUPN
transaction
Derivative
Restricted Stock Units
Disposed to Issuer
- Transaction value
- $0
- Shares
- -5,369
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 22 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,369
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
Footnote F2
These restricted stock units were settled in common stock upon vesting, which occurred on February 22, 2025.